Analysis of Traffic Splitting Mechanisms for 2D Mesh Sensor Networks

Huimin She,Zhonghai Lu,Axel Jantsch,Li-Rong Zheng,Dian Zhou 보안공학연구지원센터 2008 International Journal of Software Engineering and Vol.2 No.3

For many applications of sensor networks, it is essential to ensure that messages are transmitted to their destinations within delay bounds and the buffer size of each sensor node is as small as possible. In this paper, we firstly introduce the system model of a mesh sensor network. Based on this system model, the expressions for deriving the delay bound and buffer requirement bound are presented using network calculus theory. In order to balance traffic load and improve resource utilization, three traffic splitting mechanisms are proposed. And the two bounds are derived in these traffic splitting mechanisms. To show how our method applies to real applications, we conduct a case study on a fresh food tracking application, which monitors the food freshness status in real-time during transportation. The numerical results show that the delay bound and buffer requirement bound are reduced while applying traffic splitting mechanisms. Thus the performance of the whole sensor network is improved with less cost.

Improving Dielectric Properties in Novel P(VDF‑HFP)/V2AlC MAX/Montmorillonite Composite Films via Interfacial Electric‑Leakage Depressing Strategy

Xiaofeng Xia,Junquan Zhou,Huimin Ding,Qin Li,Maolin Bo,Qihuang Deng,Yefeng Feng 대한금속·재료학회 2021 ELECTRONIC MATERIALS LETTERS Vol.17 No.1

Dielectric constants of polymer/conductor composites are often high, owing to strong interface interaction in those composites. They can be used for dielectric energy storage, but they usually have high dielectric loss and conductivity. In order toreduce the dielectric loss and conductivity in poly(vinylidene fluoride-hexafluoropropylene) (P(VDF-HFP))/V2AlC MAXcomposites, in this study, we explored the novel P(VDF-HFP)/V2AlC MAX/montmorillonite (MMT) ternary composites. Compared with binary composites, the ternary composites showed the mildly reduced dielectric constant, significantlydecreased dielectric loss and conductivity. Using highly-conductive V2AlCMAX filler aimed at taking advantage of thepolymer/MAX interface polarization to increase the dielectric response of composites. Employing well-insulating MMTfiller aimed at reducing the interface electric leakage conduction. At 1 kHz, the outstanding ternary composite with 2 wt%MMT and 20 wt% MAX could exhibit a high dielectric constant of ca. 27 and low dielectric loss of ca. 0.21. This workmight offer a new research idea for the construction of high-performance composite dielectric films containing modernMAX ceramic fillers.

Study on the pore/scratch-strength response of ZrB2–SiC ceramic via laser processing

Wang Anzhe,Wang Shuai,Yin Huimin,Zhou Peng,Liu Dazhao 한국세라믹학회 2022 한국세라믹학회지 Vol.59 No.6

Defects, such as pores and scratches, are inevitably introduced during preparation and processing of ceramics. How they aff ect the mechanical properties of materials is worthy of attention. Here, artifi cial surface pores and notches introduced by femtosecond/nanosecond lasers are regarded as inherent pore- and scratch-like defects. Bending test results indicated that a small-sized fl aw with the length and depth of ~ 10 μm could lead to a strength reduction up to ~ 40% in sharp fl aw case, while only slight attenuation (< 10%) occurs in blunt fl aw case. Linear extrapolation result reveals that the maximum strength in notch cases, when the depth reaches the atomic scale, is ~ 34 GPa, which is in the range of the theoretical value of 24–48 GPa. Furthermore, the calculated critical fl aw size ( ac) may tend to be overestimated, given that the artifi cial defect, which is smaller than the ac value, also results in signifi cant strength decay. This study could provide guidance for strength evalu- ation and high-strength design of ceramics.

Appraisal of Guidelines for the Management of Blood Pressure in Patients with Diabetes Mellitus: The Consensuses, Controversies and Gaps

Menghui Liu,Shaozhao Zhang,Xiaohong Chen,Yue Guo,Xiangbin Zhong,Zhenyu Xiong,Yifen Lin,Huimin Zhou,Yiquan Huang,Zhengzhipeng Zhang,Lichun Wang,Xiaodong Zhuang,Xinxue Liao 대한당뇨병학회 2021 Diabetes and Metabolism Journal Vol.45 No.5

Background: Currently available guidelines contain conflicting recommendations on the management of blood pressure (BP) in patients with diabetes mellitus (DM). Therefore, it is necessary to appraise the guidelines and summarize the agreements and differences among recommendations.Methods: Four databases and the websites of guideline organizations were searched for guidelines regarding BP targets and thresholds for pharmacologic therapy in DM patients, and the included guidelines were appraised with the Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument.Results: In 6,498 records identified, 20 guidelines met our inclusion criteria with 64.0% AGREE II scores (interquartile range, 48.5% to 72.0%). The scores of the European and American guidelines were superior to those of the Asian guidelines (both adjusted P<0.001). Most of the guidelines advocated systolic BP targets <130 mm Hg (12 guidelines, 60%) and diastolic BP targets <80 mm Hg (14 guidelines, 70%) in DM patients. Approximately half of the guidelines supported systolic BP thresholds >140 mm Hg (10 guidelines, 50%) and diastolic BP thresholds >90 mm Hg (nine guidelines, 45%). The tiny minority of the guidelines provided the relevant recommendations regarding the lower limit of official BP targets and the ambulatory BP monitoring (ABPM)/home BP monitoring (HBPM) targets and thresholds in DM patients.Conclusion: The lower official BP targets (<130/80 mm Hg) in patients with DM are advocated by most of the guidelines, but they contain conflicting recommendations on the official BP thresholds. Moreover, the gaps regarding the lower limit of official BP targets and the ABPM/HBPM targets and thresholds need to be considered by future study.

MicroRNA-375 is a therapeutic target for castration-resistant prostate cancer through the PTPN4/STAT3 axis

Gan Junqing,Liu Shan,Zhang Yu,He Liangzi,Bai Lu,Liao Ran,Zhao Juan,Guo Madi,Jiang Wei,Li Jiade,Li Qi,Mu Guannan,Wu Yangjiazi,Wang Xinling,Zhang Xingli,Zhou Dan,Lv Huimin,Wang Zhengfeng,Zhang Yanqiao,Q 생화학분자생물학회 2022 Experimental and molecular medicine Vol.54 No.-

The functional role of microRNA-375 (miR-375) in the development of prostate cancer (PCa) remains controversial. Previously, we found that plasma exosomal miR-375 is significantly elevated in castration-resistant PCa (CRPC) patients compared with castration-sensitive PCa patients. Here, we aimed to determine how miR-375 modulates CRPC progression and thereafter to evaluate the therapeutic potential of human umbilical cord mesenchymal stem cell (hucMSC)-derived exosomes loaded with miR-375 antisense oligonucleotides (e-375i). We used miRNA in situ hybridization technique to evaluate miR-375 expression in PCa tissues, gain- and loss-of-function experiments to determine miR-375 function, and bioinformatic methods, dual-luciferase reporter assay, qPCR, IHC and western blotting to determine and validate the target as well as the effects of miR-375 at the molecular level. Then, e-375i complexes were assessed for their antagonizing effects against miR-375. We found that the expression of miR-375 was elevated in PCa tissues and cancer exosomes, correlating with the Gleason score. Forced expression of miR-375 enhanced the expression of EMT markers and AR but suppressed apoptosis markers, leading to enhanced proliferation, migration, invasion, and enzalutamide resistance and decreased apoptosis of PCa cells. These effects could be reversed by miR-375 silencing. Mechanistically, miR-375 directly interfered with the expression of phosphatase nonreceptor type 4 (PTPN4), which in turn stabilized phosphorylated STAT3. Application of e-375i could inhibit miR-375, upregulate PTPN4 and downregulate p-STAT3, eventually repressing the growth of PCa. Collectively, we identified a novel miR-375 target, PTPN4, that functions upstream of STAT3, and targeting miR-375 may be an alternative therapeutic for PCa, especially for CRPC with high AR levels.